{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:53:25Z","timestamp":1790420005668,"version":"4.1.0"},"reference-count":92,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,8,15]]},"DOI":"10.1086\/376971","type":"journal-article","created":{"date-parts":[[2003,8,8]],"date-time":"2003-08-08T10:39:05Z","timestamp":1060339145000},"page":"533-541","source":"Crossref","is-referenced-by-count":77,"title":["Hematologic Disorders Associated with Hepatitis C Virus Infection and Their Management"],"prefix":"10.1093","volume":"37","author":[{"given":"Douglas T.","family":"Dieterich","sequence":"first","affiliation":[{"name":"Department of Medicine, Mount Sinai Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry L.","family":"Spivak","sequence":"additional","affiliation":[{"name":"Division of Hematology, Johns Hopkins Medical Institutions, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t20180216230013_ref1","first-page":"35","article-title":"Natural history of chronic hepatitis","volume":"36","author":"Seef","year":"2002","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180216230013_ref2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ilar.42.2.107","article-title":"Hepatitis C: a brief clinical overvie","volume":"42","author":"Strader","year":"2001","journal-title":"ILAR J"},{"key":"key\n\t\t\t\t20180216230013_ref3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0002-9343(99)00374-5","article-title":"Natural history of hepatitis","volume":"107","author":"Seeff","year":"1999","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20180216230013_ref4","article-title":"Management of hepatitis C: 200","volume-title":"National Institutes of Health Consensus Development Conference Statement","author":"National Institutes of Health"},{"key":"key\n\t\t\t\t20180216230013_ref5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hep.1840140111","article-title":"The significance of antibody to hepatitis C virus in patients with chronic hepatitis","volume":"14","author":"Fong","year":"1991","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180216230013_ref6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC group","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180216230013_ref7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.510260711","article-title":"Epidemiology of hepatitis","volume":"26","author":"Alter","year":"1997","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180216230013_ref8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0168-8278(96)80225-X","article-title":"Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled stud","volume":"25","author":"Dusheiko","year":"1996","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20180216230013_ref9","first-page":"67","article-title":"Safety of combination interferon alfa-2b\/ribavirin therapy in chronic hepatitis C-relapsed and treatment-na\u00efve patient","volume":"19(Suppl 1)","author":"Maddrey","year":"1999","journal-title":"Semin Liver Dis"},{"key":"key\n\t\t\t\t20180216230013_ref10","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized tria","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180216230013_ref11","volume-title":"Rebetron (Rebetol [ribavirin]\/Intron A [interferon alfa-2b, recombinant]) [package insert]","year":"2002"},{"key":"key\n\t\t\t\t20180216230013_ref12","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0140-6736(00)02249-2","article-title":"The blood in systemic disorder","volume":"355","author":"Spivak","year":"2000","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180216230013_ref13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00004836-200103000-00015","article-title":"Autoimmune hemolytic anemia in treatment-na\u00efve chronic hepatitis C infectio","volume":"32","author":"Srinivasan","year":"2001","journal-title":"J Clin Gastroenterol"},{"key":"key\n\t\t\t\t20180216230013_ref14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/00004836-200109000-00014","article-title":"Chronic hepatitis C virus infection associated with primary warm-type autoimmune hemolytic anemi","volume":"33","author":"Chao","year":"2001","journal-title":"J Clin Gastroenterol"},{"key":"key\n\t\t\t\t20180216230013_ref15","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1053\/jhep.2002.32486","article-title":"Peripheral blood count abnormalities among patients with hepatitis C in the United State","volume":"35","author":"Streiff","year":"2002","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180216230013_ref16","first-page":"256","article-title":"Autoimmune hemolytic anemia in chronic hepatitis C virus infection: an unusual extrahepatic autoimmune manifestatio","volume":"16","author":"Moccia","year":"2001","journal-title":"Ann Ital Med Int"},{"key":"key\n\t\t\t\t20180216230013_ref17","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1053\/gast.1996.v111.pm8898645","article-title":"Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis","volume":"111","author":"Lai","year":"1996","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180216230013_ref18","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Grou","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180216230013_ref19","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180216230013_ref20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(97)06088-1","article-title":"Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Grou","volume":"351","author":"Reichard","year":"1998","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180216230013_ref21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00042737-200206000-00007","article-title":"High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection: a randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin. Swedish HCV Treatment Grou","volume":"14","author":"Verbaan","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180216230013_ref22","first-page":"57","article-title":"Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis","volume":"19(Suppl 1)","author":"McHutchison","year":"1999","journal-title":"Semin Liver Dis"},{"key":"key\n\t\t\t\t20180216230013_ref23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/jama.285.2.193","article-title":"Interferon and ribavirin vs interferon alone in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trial","volume":"285","author":"Cummings","year":"2001","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180216230013_ref24","first-page":"103","article-title":"Interferon-alpha2a\/ribavirin versus interferon-alpha2a alone for the retreatment of hepatitis C patients who relapse after a standard course of interfero","volume":"114","author":"Chapman","year":"2001","journal-title":"N Z Med J"},{"key":"key\n\t\t\t\t20180216230013_ref25","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0168-8278(02)00071-5","article-title":"Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alon","volume":"36","author":"de Ledinghen","year":"2002","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20180216230013_ref26","first-page":"CD002234","article-title":"Ribavirin with or without alpha interferon for chronic hepatitis C (Cochrane Review","volume":"2","author":"Kjaergard","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20180216230013_ref27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1365-2036.2002.01162.x","article-title":"Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapser","volume":"16","author":"Moreno-Monteagudo","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180216230013_ref28","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/jhep.2000.19347","article-title":"Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis","volume":"32","author":"Poynard","year":"2000","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180216230013_ref29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3949\/ccjm.69.2.155","article-title":"Advances in treatment of chronic hepatitis C: \u201cpegylated \u201dinterferon","volume":"69","author":"Sharieff","year":"2002","journal-title":"Cleve Clin J Med"},{"key":"key\n\t\t\t\t20180216230013_ref30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/jhep.2001.26371","article-title":"A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis","volume":"34","author":"Lindsay","year":"2001","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180216230013_ref31","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitic C virus infectio","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180216230013_ref32","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.2165\/00003495-200161150-00013","article-title":"Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis","volume":"61","author":"Perry","year":"2001","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20180216230013_ref33","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJM200012073432302","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosi","volume":"343","author":"Heathcote","year":"2000","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180216230013_ref34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/jhep.2001.21747","article-title":"Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis","volume":"33","author":"Reddy","year":"2001","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180216230013_ref35","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis","volume":"343","author":"Zeuzem","year":"2000","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180216230013_ref36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0168-8278(02)80001-0","article-title":"Peginterferon alfa-2a (40KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose [abstract 536","volume":"26(Suppl 1)","author":"Hadziyannis","year":"2002","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20180216230013_ref37","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180216230013_ref38","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1440-1746.2002.02777.x","article-title":"Hepatitis C advances in antiviral therapy: what is accepted treatment now","volume":"17","author":"McHutchison","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180216230013_ref39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/gast.2002.34175","article-title":"Rapid suppression of hematopoiesis by standard or pegylated interferon-\u03b1","volume":"123","author":"Peck-Radosavljevic","year":"2002","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180216230013_ref40","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/jhep.2002.36502","article-title":"Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis","volume":"36","author":"Soza","year":"2002","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180216230013_ref41","volume-title":"PEG-Intron (peginterferon alfa-2b) [package insert]","year":"2002"},{"key":"key\n\t\t\t\t20180216230013_ref42","volume-title":"Pegasys (peginterferon alfa-2a, recombinant) [package insert]","year":"2002"},{"key":"key\n\t\t\t\t20180216230013_ref43","volume-title":"Roferon-A (interferon alfa-2a, recombinant) [package insert]","year":"2002"},{"key":"key\n\t\t\t\t20180216230013_ref44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0041-008X(84)90139-X","article-title":"Hematological and bone marrow effects of ribavirin in rhesus monkey","volume":"74","author":"Canonico","year":"1984","journal-title":"Toxicol Appl Pharmacol"},{"key":"key\n\t\t\t\t20180216230013_ref45","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/he.2000.5789","article-title":"Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damag","volume":"31","author":"de Franceschi","year":"2000","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180216230013_ref46","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0168-8278(01)00029-0","article-title":"Factors influencing ribavirin-induced hemolysis. BASL Steering Committe","volume":"34","author":"Van Vlierbergh","year":"2001","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20180216230013_ref47","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/08860229109022152","article-title":"Investigations on the subclinical and clinical nephrotoxicity of interferon alpha-2B in patients with myeloproliferative syndrome","volume":"13","author":"Kurschel","year":"1991","journal-title":"Ren Fail"},{"key":"key\n\t\t\t\t20180216230013_ref48","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1200\/JCO.1995.13.9.2401","article-title":"Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemi","volume":"13","author":"Sacchi","year":"1995","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180216230013_ref49","first-page":"1310","article-title":"Interferon-alpha-induced apoptosis in human erythroid progenitor","volume":"23","author":"Tarumi","year":"1995","journal-title":"Exp Hematol"},{"key":"key\n\t\t\t\t20180216230013_ref50","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.1998.16.10.3412","article-title":"Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Grou","volume":"16","author":"Demetri","year":"1998","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180216230013_ref51","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2001.19.11.2875","article-title":"Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosin","volume":"19","author":"Gabrilove","year":"2001","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180216230013_ref52","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Epoetin alfa Study Grou","volume":"19","author":"Littlewood","year":"2001","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180216230013_ref53","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1086\/520178","article-title":"Human immunodeficiency virus infection, anemia, and surviva","volume":"29","author":"Moore","year":"1999","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180216230013_ref54","first-page":"474","article-title":"Recombinant human erythropoietin and health-related quality of life of AIDS patients with anemi","volume":"7","author":"Revicki","year":"1994","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180216230013_ref55","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/00002030-199905280-00010","article-title":"Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europ","volume":"13","author":"Mocroft","year":"1999","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180216230013_ref56","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1023\/A:1017964002402","article-title":"Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis","volume":"47","author":"Sagir","year":"2002","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20180216230013_ref57","first-page":"238","article-title":"Recombinant human erythropoietin therapy in haemodialysis patients\u2014dose determination and clinical experienc","volume":"2","author":"Bommer","year":"1987","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180216230013_ref58","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM198701083160203","article-title":"Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical tria","volume":"316","author":"Eschbach","year":"1987","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180216230013_ref59","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1258\/0956462001915020","article-title":"Epoetin alfa therapy for anemia in HIV-infected patients: impact on quality of lif","volume":"11","author":"Abrams","year":"2000","journal-title":"Int J STD AIDS"},{"key":"key\n\t\t\t\t20180216230013_ref60","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199005243222103","article-title":"Recombinant human erythropoietin for patients with AIDS treated with zidovudin","volume":"322","author":"Fischl","year":"1990","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180216230013_ref61","first-page":"322","article-title":"Once-weekly dosing of 40,000 U epoetin alfa is as effective as thrice-weekly dosing among anemic HIV+ patients [abstract 254]. 010 Study Grou","volume-title":"Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago)","author":"Grossman","year":"2001"},{"key":"key\n\t\t\t\t20180216230013_ref62","doi-asserted-by":"crossref","first-page":"739","DOI":"10.7326\/0003-4819-117-9-739","article-title":"Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy: overview of four clinical trial","volume":"117","author":"Henry","year":"1992","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180216230013_ref63","first-page":"1209","article-title":"Once-weekly epoetin alfa increases hemoglobin and improves quality of life in anemic HIV+ patients [abstract 708]. CHAMPS Study Grou","volume-title":"Program and abstracts of the 39th annual meeting of the Infectious Diseases Society of America (San Francisco)","author":"Saag","year":"2001"},{"key":"key\n\t\t\t\t20180216230013_ref64","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.1997.15.3.1218","article-title":"Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Grou","volume":"15","author":"Glaspy","year":"1997","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180216230013_ref65","first-page":"21","article-title":"Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studie","volume":"21(Suppl 3)","author":"Henry","year":"1994","journal-title":"Semin Oncol"},{"key":"key\n\t\t\t\t20180216230013_ref66","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1200\/JCO.2001.19.21.4126","article-title":"Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherap","volume":"19","author":"Quirt","year":"2001","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180216230013_ref67","first-page":"50","article-title":"The US Recombinant Human Erythropoietin Predialysis Study Grou","volume":"18","author":"Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20180216230013_ref68","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/jhep.2002.32529","article-title":"Treatment of ribavirin\/interferon-induced anemia with erythropoietin in patients with hepatitis","volume":"35","author":"Gergely","year":"2002","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180216230013_ref69","first-page":"66","article-title":"Once-weekly recombinant human erythropoietin (epoetin alfa) facilitates optimal ribavirin (RBV) dosing in hepatitis C virus-infected patients receiving interferon-\u03b1-2b (IFN)\/RBV therapy [abstract 18","volume-title":"Program and abstracts of the Hepatitis Single Topic Conference (Chicago)","author":"Sulkowski","year":"2001"},{"key":"key\n\t\t\t\t20180216230013_ref70","first-page":"2802","article-title":"A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-\u03b1","volume":"96","author":"Talal","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180216230013_ref71","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12 item short form health survey: construction of scales and preliminary tests of reliability and validit","volume":"34","author":"Ware","year":"1996","journal-title":"Med Care"},{"key":"key\n\t\t\t\t20180216230013_ref72","volume-title":"Neupogen (recombinant human G-CSF, filgrastim) [package insert]","year":"2002"},{"key":"key\n\t\t\t\t20180216230013_ref73","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2000.18.20.3558","article-title":"2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Pane","volume":"18","author":"Ozer","year":"2000","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180216230013_ref74","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1056\/NEJM198806023182202","article-title":"Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urotheliu","volume":"318","author":"Gabrilove","year":"1988","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180216230013_ref75","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1182\/blood.V90.12.4710","article-title":"A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission, induction, and consolidation therapy for adults with de novo acute myeloid leukemi","volume":"90","author":"Heil","year":"1997","journal-title":"Blood"},{"key":"key\n\t\t\t\t20180216230013_ref76","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/mccm.6.3.149.154","article-title":"Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patient","volume":"6","author":"Fukuda","year":"2000","journal-title":"Cytokines Cell Mol Ther"},{"key":"key\n\t\t\t\t20180216230013_ref77","first-page":"907","article-title":"Combination treatment of advanced HCV associated liver disease with interferon and G-CS","volume":"42","author":"Van Thiel","year":"1995","journal-title":"Hepatogastroenterology"},{"key":"key\n\t\t\t\t20180216230013_ref78","first-page":"429","article-title":"Use of granulocyte colony stimulating factor (GCSF) for interferon induced neutropenia in patients with chronic hepatitis C infection [abstract 1029","volume-title":"Program and abstracts of the 52nd annual meeting of the American Association for the Study of Liver Diseases (Dallas, TX)","author":"Sood","year":"2001"},{"key":"key\n\t\t\t\t20180216230013_ref79","volume-title":"Management of side effects in hepatitis C treatment","author":"Hepatitis Resource Network","year":"2001"},{"key":"key\n\t\t\t\t20180216230013_ref80","volume-title":"Neulasta (pegylated recombinant human G-CSF; pegfilgrastim) [package insert]","year":"2002"},{"key":"key\n\t\t\t\t20180216230013_ref81","volume-title":"Neumega (recombinant human IL-11; oprelvekin) [package insert]","year":"2002"},{"key":"key\n\t\t\t\t20180216230013_ref82","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/blood.V87.9.3615.bloodjournal8793615","article-title":"A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherap","volume":"87","author":"Gordon","year":"1996","journal-title":"Blood"},{"key":"key\n\t\t\t\t20180216230013_ref83","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.1997.15.11.3368","article-title":"Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubici","volume":"15","author":"Isaacs","year":"1997","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180216230013_ref84","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1177\/00912700022009521","article-title":"Mechanism and amelioration of recombinant human interleukin-11 (rhIL-11)-induced anemia in healthy subject","volume":"40","author":"Dykstra","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180216230013_ref85","first-page":"361","article-title":"Safety and efficacy of recombinant human IL-11 (oprelvekin) in combination with interferon\/ribavirin therapy in hepatitis C patients with thrombocytopenia [abstract 791","volume-title":"Program and abstracts of the 53rd annual meeting of the American Association for the Study of Liver Diseases (Boston)","author":"Rustgi","year":"2002"},{"key":"key\n\t\t\t\t20180216230013_ref86","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2893.2002.00364.x","article-title":"Fatigue in patients with chronic hepatitis","volume":"9","author":"Poynard","year":"2002","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20180216230013_ref87","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/gut.51.3.434","article-title":"Fatigue is associated with high circulating leptin levels in chronic hepatitis","volume":"51","author":"Piche","year":"2002","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180216230013_ref88","first-page":"671","article-title":"Hematologic complications of HIV infectio","volume":"10","author":"Hambleton","year":"1996","journal-title":"Oncology"},{"key":"key\n\t\t\t\t20180216230013_ref89","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood.V95.12.3986","article-title":"Detection of active hepatitis C virus and hepatitis G virus\/GB virus C replication in bone marrow in human subject","volume":"95","author":"Radkowski","year":"2000","journal-title":"Blood"},{"key":"key\n\t\t\t\t20180216230013_ref90","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/ajh.1180","article-title":"Treatment of hepatitis C related thrombocytopenia with interferon alph","volume":"68","author":"Rajan","year":"2001","journal-title":"Am J Hematol"},{"key":"key\n\t\t\t\t20180216230013_ref91","first-page":"17","article-title":"Thrombocytopenia in patients with HCV-positive chronic hepatitis: efficacy of leucocyte interferon-alpha treatmen","volume":"57","author":"Benci","year":"2003","journal-title":"Int J Clin Pract"},{"key":"key\n\t\t\t\t20180216230013_ref92","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1046\/j.1365-2141.2000.02132.x","article-title":"HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant alpha-2b-interferon therap","volume":"110","author":"Garcia-Suarez","year":"2000","journal-title":"Br J Haematol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/37\/4\/533\/23992407\/37-4-533.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T06:15:14Z","timestamp":1585116914000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/37\/4\/533\/331606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,8,15]]}},"URL":"https:\/\/doi.org\/10.1086\/376971","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2003,8]]},"published":{"date-parts":[[2003,8]]}}}